Serina Therapeutics, Inc. filed a Certificate of Elimination with the Secretary of State of Delaware on October 5, 2026. The filing removes all matters related to the Series A Convertible Preferred Stock from the company’s First Amended and Restated Certificate of Incorporation.
The Series A Preferred Stock is a class of shares with a par value of $0.0001 per share. The filing indicates that none of these shares are currently outstanding. All issued and outstanding shares of Series A Preferred Stock have already been converted into shares of the company’s common stock.
The Certificate of Elimination was filed pursuant to Section 151(g) of the General Corporation Law of the State of Delaware. Upon the filing, the shares previously designated as Series A Preferred Stock reverted to the status of authorized but unissued shares of preferred stock, without a specific series designation.
The filing was signed by Steve Ledger, the Chief Executive Officer of Serina Therapeutics, on October 9, 2026.
